| Cat. No. |
Product Name |
Information |
| PC-38578 |
JBJ-08-178-01
HER2 inhibitor
|
JBJ-08-178-01 is a potent, selective and covalent HER2 inhibitor with IC50 of 2.21 nM and 7.04 nM for HER2 WT and EGFR WT, targets multiple HER2 activating mutations, including exon 20 insertions as well as amplification (IC50 values<50 nM). |
| PC-38536 |
TX1-85-1
ErbB3 inhibitor
|
TX1-85-1 is a potent, selective, irreversible and covalent inhibitor of pseudokinase Her3 (ErbB3) with IC50 of 23 nM in FRET-based binding assay. |
| PC-38348 |
LS-106
EGFR mutant inhibitor
|
LS-106 is a novel, fourth-generation EGFR inhibitor against C797S mutation, targeting both EGFR19del/T790M/C797S and EGFRL858/T790M/C797S with selectivity over EGFRwt. |
| PC-38347 |
ASK120067
EGFR mutant inhibitor
|
ASK120067 (Limertinib) is a novel third-generation inhibitor of EGFR T790M (L858R/T790M IC50=0.3 nM, T790M IC50=0.5 nM), with selectivity over EGFR WT (IC50=6 nM). |
| PC-38346 |
TAS-121
EGFR mutant inhibitor
|
TAS-121 (TAS 121) is an orally available, potent, novel third-generation EGFR-TKI that selectively targets EGFR activating and T790M resistance mutations, sparing wild-type EGFR. |
| PC-38345 |
Oritinib mesylate
mutant EGFR inhibitor
|
Oritinib mesylate (SH-1028) is an irreversible third-generation EGFR inhibitor, selectively and specifically inhibits EGFR active mutations and T790M resistance mutations, sparing wild-type EGFR. |
| PC-38344 |
Oritinib
mutant EGFR inhibitor
|
Oritinib (SH-1028) is an irreversible third-generation EGFR inhibitor, selectively and specifically inhibits EGFR active mutations and T790M resistance mutations, sparing wild-type EGFR. |
| PC-38343 |
Rezivertinib
EGFR inhibitor
|
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance. |
| PC-38342 |
Almonertinib
EGFR inhibitor
|
Aumolertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations with IC50 of 0.37 nM (T790M), 0.21 nM (del19/T790M), 0.29 nM(L858R/T790M), and 3.39 nM (EGFR WT). |
| PC-38341 |
Befotertinib
EGFR inhibitor
|
Befotertinib (D-0316) is an orally active, third-generation EGFR tyrosine kinase inhibitor that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in NSCLC. |
| PC-73366 |
JBJ-09-063
EGFR mutant inhibitor
|
JBJ-09-063 is a potent, mutant-selective allosteric EGFR inhibitor against EGFR L858R, T790M and C797S mutations, with IC50 of <0.1 nM for recombinant EGFR L858R/T790M kinase domain. |
| PC-73295 |
DDC-03-024-01
EGFR mutant inhibitor
|
DDC-03-024-01 is a potent, mutant-selective allosteric inhibitor of EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with IC50 of 10 nM. |
